#USA #Boulder #Transformative Biotech #Mark Kelleher #Extraction-free PCR

Transformative Biotech Welcomes Dr. Mark Kelleher as Executive VP of R&D

Transformative Biotech has taken a significant step forward in enhancing its leadership team by appointing Dr. Mark Kelleher as the Executive Vice President of Research and Development. This move is aimed at accelerating the development of the company’s extraction-free polymerase chain reaction (PCR) platform, which promises to revolutionize infectious disease testing in both clinical and point-of-care environments.

Dr. Kelleher brings a wealth of experience to Transformative Biotech, having held pivotal roles in molecular diagnostics and product development at several high-profile organizations, including 23andMe and Affymetrix. His extensive background encompasses both startup environments and established companies, making him well-suited to lead Transformative Biotech's mission to simplify molecular testing.

Kevin Kraus, the CEO of Transformative Biotech, highlighted the importance of Dr. Kelleher's expertise, stating, "Our mission is to fundamentally simplify how molecular tests are delivered and accessed. Mark's proven track record of translating molecular technologies into scalable solutions will be invaluable as we transition from innovation to clinically impactful products."

In his capacity as Executive VP of R&D, Dr. Kelleher will spearhead the development of assays and systems tied to Transformative Biotech’s patented extraction-free PCR technologies. His immediate focus will be on expanding the company’s infectious disease product portfolio and fostering collaborations with various stakeholders, including clinical, research, and industry partners.

"The proprietary extraction-free chemistry we’re developing is aimed at addressing long-standing challenges in molecular testing workflows," Dr. Kelleher commented. "Joining this accomplished team is an honor, and I’m excited about the opportunity to advance this critical work. Our goal is to create streamlined, robust direct-to-PCR solutions that minimize sample preparation complexities while ensuring high diagnostic performance for clinical applications."

Dr. Kelleher's appointment signifies a pivotal juncture for Transformative Biotech as the company seeks to accelerate its growth trajectory and make a substantial commercial impact. The firm is committed to pioneering advancements in molecular diagnostics, with a strong emphasis on making reliable testing accessible across various settings.

About Transformative Biotech

Transformative Biotech is a cutting-edge biotechnology firm dedicated to the development of rapid, highly accurate direct-to-PCR technologies designed to transform the landscape of molecular testing for infectious diseases and cancer. By leveraging proprietary patented direct-to-PCR technologies and an innovative collaborative research model, Transformative Biotech aims to empower diagnostic testing that can be conducted anywhere.

For inquiries related to media or partnerships, please reach out to Shelle Pourmanafzadehardabili, VP of Business Operations at [email protected] For general questions, contact [email protected]